PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a

New data found Pegylated Interferon-lambda (PegIFN-lambda) shows superior virological response in HCV patients of genotypes 1-4, with improved safety and tolerability, compared to Pegylated Interferon-alpha (PegIFN-alpha-2a), the current standard of care in chronic HCV.

Read the whole article on Science Daily

More from Science Daily